Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
18 studies found for:    Isaac's Syndrome
Show Display Options
Rank Status Study
1 Unknown  Inherited Myokymia: A Clinical and Genetic Study of a Family
Condition: A Study of Clinical and Genetic Mutations in a Family of Neuromyotonia, so Called Isaac's Syndrome
Intervention:
2 Active, not recruiting Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Condition: Primary Lateral Sclerosis
Intervention:
3 Terminated
Has Results
Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo
4 Completed
Has Results
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis
5 Active, not recruiting Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions: Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
6 Completed Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi
Condition: Dysplastic Nevi
Intervention: Procedure: Saucerization biopsy
7 Completed A Clinical Study of Intravenous Immunoglobulin
Condition: Immunologic Deficiency Syndromes
Intervention: Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
8 Unknown  An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
Conditions: Autism;   Autistic Disorder;   Asperger's Disorder;   PDD;   Pervasive Developmental Disorder
Intervention: Drug: Gammaplex 5%
9 Completed Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
Conditions: Primary Immunodeficiency Disorders;   Immune Thrombocytopenic Purpura (ITP);   Kawasaki Syndrome
Intervention: Biological: Immune Globulin Intravenous (Human), 10%
10 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
11 Completed
Has Results
A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases
Condition: Primary Immunodeficiency Diseases
Intervention: Biological: NewGam
12 Active, not recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer;   Stage IIB Colon Cancer;   Stage IIC Colon Cancer
Interventions: Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
13 Recruiting Breast Cancer WEight Loss Study (BWEL Study)
Condition: Breast Carcinoma
Interventions: Other: Health Education Program;   Other: Weight Loss Intervention
14 Recruiting Cups or Cash for Girls Trial to Reduce Sexual and Reproductive Harm and School Dropout
Conditions: Reproductive Health;   Herpesvirus Infection;   HIV Infections;   Woman Abuse;   Quality of Life;   Adolescent Behavior
Interventions: Device: Menstrual Cup;   Other: Cash transfer;   Other: Cups and Cash
15 Active, not recruiting Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: Lenalidomide;   Other: Pharmacological Study
16 Recruiting Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Conditions: AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma;   Stage IVB Hepatocellular Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
17 Active, not recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Endometrial Serous Adenocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Lung Carcinoid Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Metastatic Digestive System Neuroendocrine Tumor G1;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Polypeptide Tumor;   Recurrent Adult Liver Carcinoma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer;   Uterine Carcinosarcoma
Interventions: Biological: Bevacizumab;   Drug: Temsirolimus
18 Recruiting A Phase 3, Multinational, Multicenter, Open-Label Study of ProMetic BioTherapeutics IVIG
Condition: Primary Immunodeficiency
Interventions: Biological: Immune Globulin (Human) Intravenous;   Biological: Commercial Immune Globulin Intravenous

Study has passed its completion date and status has not been verified in more than two years.